Dr. Hala Borno on Addressing Disparities in Access to Prostate Cancer Care

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Hala Borno, MD, of the University of California, San Francisco, about addressing the disparities in access to clinical trials and treatments for patients with prostate cancer.

Cancer Network spoke with Hala Borno, MD, of the University of California, San Francisco, about addressing the disparities in access to clinical trials and treatments for patients with prostate cancer.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content
A combined genomic and histological analysis within trial datasets demonstrates a sound tumor evaluation strategy for patients with prostate cancer.

Tool Combining Genomics, AI May Predict Future Prostate Cancer Recurrence

Roman Fabbricatore
July 23rd 2024
Article

A combined genomic and histological analysis within trial datasets demonstrates a sound tumor evaluation strategy for patients with prostate cancer.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Developers plan to submit data from the ARANOTE trial to global regulatory health authorities to expand indications for darolutamide in metastatic HSPC.

Darolutamide Combo Improves Radiological PFS in Metastatic HSPC

Russ Conroy
July 17th 2024
Article

Developers plan to submit data from the ARANOTE trial to global regulatory health authorities to expand indications for darolutamide in metastatic HSPC.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

In a phase 1 trial, City of Hope’s CAR T-cell therapy showed minimal adverse effects and promising therapeutic activity for advanced prostate cancer.

CAR T-Cell Therapy Demonstrates Promising Results for mCRPC

Roman Fabbricatore
June 27th 2024
Article

In a phase 1 trial, City of Hope’s CAR T-cell therapy showed minimal adverse effects and promising therapeutic activity for advanced prostate cancer.

Compared with cognitively-defined and hemigland contours, AI-assisted cancer contours delivered a greater balanced accuracy rate.

AI-Assisted Contours Exhibit High Accuracy in Evaluating Prostate Cancer

Roman Fabbricatore
June 20th 2024
Article

Compared with cognitively-defined and hemigland contours, AI-assisted cancer contours delivered a greater balanced accuracy rate.